Literature DB >> 26251824

The Vulnerable Ventral Tegmental Area in Parkinson's Disease.

Stephanie L Alberico1, Martin D Cassell2, Nandakumar S Narayanan1.   

Abstract

INTRODUCTION: The involvement of dopaminergic neurons in the ventral tegmental area (VTA) in Parkinson's disease (PD) has not been universally recognized by neuroscientists and neurologists. Here, we conduct a review of previous research documenting dopaminergic neuronal loss in both the substantia nigra pars compacta (SNpc) and VTA and add three new post-mortem PD cases to the literature.
METHODS: PD and control brains were sectioned, stained for tyrosine hydroxylase, and cells in the SNpc and VTA were counted.
RESULTS: Based on the review, we report two main results: 1) the VTA does degenerate in PD, and 2) the VTA degenerates less than the SNpc.
CONCLUSION: Inconsistent clinical information about these cases limits our ability to interpret how the VTA contributes to PD symptoms. However, our data in combination with prior PD neuropathological cases in the literature unequivocally establish that the VTA is involved in PD, and could be relevant for future investigation of non-motor symptoms in PD.

Entities:  

Keywords:  Parkinson’s disease; Ventral tegmental area

Year:  2015        PMID: 26251824      PMCID: PMC4523275          DOI: 10.1016/j.baga.2015.06.001

Source DB:  PubMed          Journal:  Basal Ganglia        ISSN: 2210-5336


  53 in total

1.  What predicts mortality in Parkinson disease?: a prospective population-based long-term study.

Authors:  E B Forsaa; J P Larsen; T Wentzel-Larsen; G Alves
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

2.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

3.  Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration.

Authors:  N M Kanaan; J H Kordower; T J Collier
Journal:  Eur J Neurosci       Date:  2008-06       Impact factor: 3.386

4.  Vglut2 afferents to the medial prefrontal and primary somatosensory cortices: a combined retrograde tracing in situ hybridization study [corrected].

Authors:  Elizabeth E Hur; Laszlo Zaborszky
Journal:  J Comp Neurol       Date:  2005-03-14       Impact factor: 3.215

5.  Calbindin controls release probability in ventral tegmental area dopamine neurons.

Authors:  Ping-Yue Pan; Timothy A Ryan
Journal:  Nat Neurosci       Date:  2012-06       Impact factor: 24.884

6.  Mesolimbic dopaminergic dysfunction in Parkinson's disease depression: evidence from a 123I-FP-CIT SPECT investigation.

Authors:  D Frosini; E Unti; F Guidoccio; C Del Gamba; G Puccini; D Volterrani; U Bonuccelli; R Ceravolo
Journal:  J Neural Transm (Vienna)       Date:  2015-01-23       Impact factor: 3.575

7.  Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease.

Authors:  T Arendt; V Bigl; A Arendt; A Tennstedt
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

8.  Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.

Authors:  C M Waters; R Peck; M Rossor; G P Reynolds; S P Hunt
Journal:  Neuroscience       Date:  1988-05       Impact factor: 3.590

9.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

10.  Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions.

Authors:  G R Uhl; J C Hedreen; D L Price
Journal:  Neurology       Date:  1985-08       Impact factor: 9.910

View more
  52 in total

1.  Parkinsonian GM2 synthase knockout mice lacking mature gangliosides develop urinary dysfunction and neurogenic bladder.

Authors:  Carolina Gil-Tommee; Guadalupe Vidal-Martinez; C Annette Reyes; Javier Vargas-Medrano; Gloria V Herrera; Silver M Martin; Stephanie A Chaparro; Ruth G Perez
Journal:  Exp Neurol       Date:  2018-10-25       Impact factor: 5.330

Review 2.  Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.

Authors:  Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte
Journal:  Neurosci Biobehav Rev       Date:  2019-05-24       Impact factor: 8.989

3.  Prefrontal D1 Dopamine-Receptor Neurons and Delta Resonance in Interval Timing.

Authors:  Young-Cho Kim; Nandakumar S Narayanan
Journal:  Cereb Cortex       Date:  2019-05-01       Impact factor: 5.357

4.  Mid-frontal theta activity is diminished during cognitive control in Parkinson's disease.

Authors:  Arun Singh; Sarah Pirio Richardson; Nandakumar Narayanan; James F Cavanagh
Journal:  Neuropsychologia       Date:  2018-05-23       Impact factor: 3.139

5.  The relation of anxiety and cognition in Parkinson's disease.

Authors:  Gretchen O Reynolds; Kristine K Hanna; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychology       Date:  2017-04-20       Impact factor: 3.295

6.  Optogenetic Stimulation of Frontal D1 Neurons Compensates for Impaired Temporal Control of Action in Dopamine-Depleted Mice.

Authors:  Young-Cho Kim; Sang-Woo Han; Stephanie L Alberico; Rafael N Ruggiero; Benjamin De Corte; Kuan-Hua Chen; Nandakumar S Narayanan
Journal:  Curr Biol       Date:  2016-12-15       Impact factor: 10.834

7.  Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release.

Authors:  Romina Pes; Sean C Godar; Andrew T Fox; Lauren M Burgeno; Hunter J Strathman; David P Jarmolowicz; Paola Devoto; Beth Levant; Paul E Phillips; Stephen C Fowler; Marco Bortolato
Journal:  Neuropharmacology       Date:  2016-11-23       Impact factor: 5.250

8.  Prolonged increase in ser31 tyrosine hydroxylase phosphorylation in substantia nigra following cessation of chronic methamphetamine.

Authors:  Michael F Salvatore; Vicki A Nejtek; Habibeh Khoshbouei
Journal:  Neurotoxicology       Date:  2018-05-18       Impact factor: 4.294

Review 9.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

10.  Axial levodopa-induced dyskinesias and neuronal activity in the dorsal striatum.

Authors:  Stephanie L Alberico; Young-Cho Kim; Tomas Lence; Nandakumar S Narayanan
Journal:  Neuroscience       Date:  2016-12-09       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.